Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients
Effects of Fimasartan on Insulin Secretion, and Interaction With DPP4 Inhibitors in Patients With Type 2 Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-144
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 20~80 years
- Type 2 diabetic patients diagnosed more than 6 months ago
- HbA1c ≤8.5% at screening
- No change of OAD within the 3 months before screening
- SBP <140 mmHg and DBP <90 mmHg with anti-hypertensive drug at screening
- SBP ≥140 mmHg or DBP ≥80 mmHg without anti-hypertensive drug at screening
Exclusion Criteria:
- Type 1 diabetic patients or active insulin treatment at screening
- Treatment with ARB or ACEi within 1 month prior to screening
- Uncontrolled hypertension with SBP >170 mmHg or DBP >100 mmHg
- Pregnancy or lactation
- Elevated liver enzyme (AST or ALT > 3 times the UNL) or elevated serum Cr (≥1.5 mg/dL in men and 1.4 mg/dL in women)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fimasartan
Expreimental drug is fimasartan.
|
16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
|
|
Active Comparator: Amlodipine
Active comparator is amlodipine.
|
16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Insulinogenic index
Time Frame: 16 week
|
16 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
HOMA β-cell function
Time Frame: 16 week
|
16 week
|
|
Insulin resistance
Time Frame: 16 week
|
16 week
|
|
Urinary albumin creatinine ratio, urinary protein creatinine ratio
Time Frame: 16 week
|
16 week
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Fimasartan study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.